{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:08:20Z","timestamp":1788433700365,"version":"build-2803163510"},"reference-count":18,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,13]]},"DOI":"10.1182\/bloodadvances.2024015292","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:02:31Z","timestamp":1740171751000},"page":"2302-2306","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["BR or R-CHOP induction with rituximab maintenance in untreated, transplant-ineligible patients with mantle cell lymphoma"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3948-6186","authenticated-orcid":false,"given":"Katja","family":"Gutmair","sequence":"first","affiliation":[{"name":"1Institute for Medical Information Processing, Biometry, and Epidemiology, Ludwig Maximilian University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4625-3009","authenticated-orcid":false,"given":"Diego","family":"Villa","sequence":"additional","affiliation":[{"name":"2Division of Medical Oncology, BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Cunningham","sequence":"additional","affiliation":[{"name":"3Belfast Health and Social Care Trust, Belfast, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2676-0860","authenticated-orcid":false,"given":"Elisabeth","family":"Silkenstedt","sequence":"additional","affiliation":[{"name":"4Department of Medicine III, University Hospital Ludwig Maximilian University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Rimsza","sequence":"additional","affiliation":[{"name":"5Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4991-7712","authenticated-orcid":false,"given":"Colleen","family":"Ramsower","sequence":"additional","affiliation":[{"name":"5Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0435-5947","authenticated-orcid":false,"given":"David W.","family":"Scott","sequence":"additional","affiliation":[{"name":"2Division of Medical Oncology, BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4727-1425","authenticated-orcid":false,"given":"Alina S.","family":"Gerrie","sequence":"additional","affiliation":[{"name":"2Division of Medical Oncology, BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2617-9427","authenticated-orcid":false,"given":"Hanneke C.","family":"Kluin-Nelemans","sequence":"additional","affiliation":[{"name":"6Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0358-5249","authenticated-orcid":false,"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[{"name":"4Department of Medicine III, University Hospital Ludwig Maximilian University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0749-1389","authenticated-orcid":false,"given":"Eva","family":"Hoster","sequence":"additional","affiliation":[{"name":"1Institute for Medical Information Processing, Biometry, and Epidemiology, Ludwig Maximilian University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"issue":"12","key":"2025051213265881900_bib1","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"2025051213265881900_bib2","doi-asserted-by":"crossref","first-page":"7501","DOI":"10.1200\/JCO.2017.35.15_suppl.7501","article-title":"Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: nine-year updated results from the StiL NHL1 study","volume":"35","author":"Rummel","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025051213265881900_bib3","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1200\/JCO.19.01294","article-title":"Treatment of older patients with mantle cell lymphoma (MCL): long-term follow-up of the randomized European MCL Elderly trial","volume":"38","author":"Kluin-Nelemans","year":"2020","journal-title":"J Clin Oncol"},{"issue":"13","key":"2025051213265881900_bib4","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N Engl J Med"},{"issue":"14","key":"2025051213265881900_bib5","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US Lymphoma CAR T Consortium","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025051213265881900_bib6","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025051213265881900_bib7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.beha.2017.07.006","article-title":"What is the optimal initial management of the older MCL patient?","volume":"31","author":"Kluin-Nelemans","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"issue":"9873","key":"2025051213265881900_bib8","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"suppl 1","key":"2025051213265881900_bib9","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1182\/blood-2024-199710","article-title":"Ibrutinib-rituximab is superior to rituximab-chemotherapy in previously untreated older mantle cell lymphoma patients: results from the international randomised controlled trial, Enrich","volume":"144","author":"Lewis","year":"2024","journal-title":"Blood"},{"issue":"3","key":"2025051213265881900_bib10","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1200\/JCO.21.02698","article-title":"Treatment outcomes and roles of transplantation and maintenance rituximab in patients with previously untreated mantle cell lymphoma: results from large real-world cohorts","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"15","key":"2025051213265881900_bib11","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1182\/bloodadvances.2020002068","article-title":"Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma","volume":"4","author":"Villa","year":"2020","journal-title":"Blood Adv"},{"issue":"18","key":"2025051213265881900_bib12","doi-asserted-by":"crossref","first-page":"5285","DOI":"10.1182\/bloodadvances.2022007371","article-title":"Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma","volume":"6","author":"Villa","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"2025051213265881900_bib13","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"issue":"12","key":"2025051213265881900_bib14","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","article-title":"Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network","volume":"34","author":"Hoster","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9","key":"2025051213265881900_bib15","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1038\/s41375-023-01977-y","article-title":"Clinical outcome of mantle cell lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)","volume":"37","author":"Scheubeck","year":"2023","journal-title":"Leukemia"},{"issue":"17","key":"2025051213265881900_bib16","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2025051213265881900_bib17","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/bjh.15519","article-title":"Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network","volume":"184","author":"Rauert-Wunderlich","year":"2019","journal-title":"Br J Haematol"},{"issue":"1","key":"2025051213265881900_bib18","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/bjh.19153","article-title":"Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine-rituximab","volume":"204","author":"Ramsower","year":"2024","journal-title":"Br J Haematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/9\/2302\/2373358\/blooda_adv-2024-015292-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/9\/2302\/2373358\/blooda_adv-2024-015292-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T17:27:05Z","timestamp":1747070825000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/9\/2302\/535660\/BR-or-R-CHOP-induction-with-rituximab-maintenance"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,5,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015292","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,5]]}}}